JPJieun Park

Jieun Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jieun Park has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Matthew Shane Loop

    Affiliations Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Alabama, United States of America, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina, United States of America

    3 shared publications
  • Daniel I. Feig

    Division of Pediatric Nephrology, Heersink School of Medicine, University of Alabama at Birmingham, Alabama, United States of America

    2 shared publications
  • Kaniz Afroz Tanni

    Department of Health Outcomes Research and Policy, Harrison College of Pharmacy, Auburn University, Alabama, United States of America

    2 shared publications
  • Keia R. Sanderson

    Division of Nephrology and Hypertension, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Matthew M. Laughon

    Division of Neonatal-Perinatal Medicine, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, North Carolina, United States of America

    2 shared publications
  • Alejandro D. Perez

    UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Pharmacist-led Transitions of Care Intervention to Address Infectious Disease Tests Pending at Discharge (TPAD)

    by Elizabeth W Covington, Matthew Shane Loop, Jieun Park, Leborah Lee, Mary Bowman, Sarah Grace Gunter

    Background: Infectious disease test results frequently finalize after hospital discharge, and many are clinically actionable. Standardized workflows for reviewing these results remain limited. Although pharmacist-led culture follow-up is well established in emergency departments, evidence evaluating inpatient transitions-of-care models is sparse. This study assessed the impact of a pharmacist-led service on outpatient antimicrobial appropriateness and clinical outcomes. Methods: We conducted a single-center, retrospective pre–post study at a community hospital comparing patients discharged with pending infectious disease test results before and after service implementation. The intervention included thrice-weekly review of finalized results, clinical assessment, prescriber communication, outpatient prescription changes, and patient counseling. The primary outcome was appropriate outpatient antimicrobial therapy 7 days after discharge. Secondary outcomes included time to appropriate therapy among patients requiring prescription modification and 30-day infection-related outcomes. Multivariable logistic regression adjusted for urine culture source, discharge service, and inpatient infectious diseases consultation. Time-to-therapy analyses used Kaplan–Meier and Cox proportional hazards. Results: Among 191 patients (93 preintervention; 98 postintervention), appropriate antimicrobial therapy at 7 days increased from 69% to 92%. Adjusted analyses showed a 21.3% higher predicted probability of appropriate therapy (95% CI, 10.6–32.0). Among patients requiring prescription changes (n = 63), median time to appropriate therapy improved from 7 to 4 days, with a 5-fold higher rate of achieving appropriate therapy (hazard ratio, 5.09; 95% CI, 2.13–12.18). Thirty-day outcomes were similar between groups. Conclusions: A pharmacist-led service improved antimicrobial appropriateness and accelerated transitions to appropriate therapy, supporting pharmacist-driven follow-up as an effective stewardship strategy.

  • Open Access

    Dosing trajectories of antihypertensive agents among preterm neonates: A retrospective, cross-sectional analysis

    by Mary-Carty Pittman, Alejandro D. Perez, Kaniz Afroz Tanni, Keia R. Sanderson, Jieun Park, Daniel I. Feig, Matthew M. Laughon, Matthew Shane Loop

    Introduction: Preterm infants are at increased risk for hypertension due to incomplete organ development. With no established guidelines for treating hypertension in this population, clinicians rely on their experience, and little is known regarding those treatment decisions. This study described dosing trajectories for the three most common antihypertensive agents in preterm infants. Methods: This retrospective, cross-sectional study examined preterm neonates (gestational age at birth < 37 weeks, postmenstrual age < 44 weeks) treated with antihypertensive medications at the University of Alabama at Birmingham (UAB) Medical Center. The study identified the three most common antihypertensive agents and identified common dosing patterns over time using the functional K-means algorithm. We then compared demographic and clinical information across these clusters. Results: The study included 87 patients across 93 visits. The three most common antihypertensive agents were propranolol (61%), captopril (8.8%), and esmolol (12%). Median treatment durations were 292 hours for propranolol, 186 hours for captopril, and 68 hours for esmolol. Propranolol was often initiated at a dose that was maintained with few dosing changes. Patients needing higher doses of propranolol were generally younger gestational age and spent longer in the hospital. Captopril doses started low and increased over time, likely due to safety concerns. Esmolol showed the most variable dosing trajectories. Conclusions: Propranolol is often initiated at a target dose and maintained with less titration, while both captopril and esmolol are titrated more often. Younger gestational age patients typically required higher doses of propranolol.

  • Open Access

    Sequence of antihypertensive medications used in preterm infants with hypertension: A cross-sectional study

    by Alejandro D. Perez, Mary-Carty Pittman, Kaniz Afroz Tanni, Keia R. Sanderson, Jieun Park, Daniel I. Feig, Matthew M. Laughon, Matthew Shane Loop

    Background: Hypertension in preterm infants can result in life-threatening outcomes. However, there is limited evidence to guide the pharmacologic management of hypertension in preterm infants. Without population-level studies of the pharmacologic strategies that clinicians currently employ for hypertension in preterm infants, studies investigating the benefits and risks of these strategies cannot be performed. Methods: A retrospective, cross-sectional study was conducted at a single academic medical centerto determine the most prevalent antihypertensive medication used for first-line, second-line, and adjunctive pharmacologic management among preterm infants with hypertension. The study sample included patients with a postnatal age less than 1 year at hospital discharge, gestational age at birth less than 37 weeks, and treated with an antihypertensive medication between July 2010 and December 2022. The prevalence of each antihypertensive medication used for each stage of pharmacologic management was estimated, and prevalences were compared using prevalence ratios. Bayesian multinomial regression was used to estimate prevalence ratios and 95% credible intervals (CIs). Results: Out of 751 possibly eligible patient encounters obtained, 134 encounters were identified across 120 patients that met the inclusion criteria. Second-line and adjunctive pharmacologic management were used in 6 and 12 encounters, respectively. Propranolol had the highest prevalence for each stage of pharmacologic management: 61% for first-line (95% CI: 53-69%); 40% for second-line (95% CI: 14-70%); and 47% for adjunctive pharmacologic management (95% CI: 24-72%). As a first-line pharmacologic management, propranolol was 4.8 times (95% CI: 2.9-7.7) as prevalent as the second most prevalent medication (captopril). Conclusion: In a large academic hospital, propranolol was the most commonly used medication for first-line antihypertensive pharmacologic management among preterm infants. The most prevalent medication used for second-line and adjunctive pharmacologic management was inconclusive.

  • Open Access

    Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients

    by Stephen Weber, Kelly B. Menees, Jieun Park, Julian Agin-Liebes, Chih-Chun Lin, Roy N. Alcalay, Jae-Kyung Lee

    Mounting data suggest an important role for the immune system in Parkinson’s disease (PD). Previous evidence of increased natural killer (NK) cell populations in PD suggests a potential role of NK cells in the pathogenesis of the disease. Previous studies have analyzed NK cell populations using aggregation by variable expression of CD56 and CD16. It remains unknown what differences may exist between NK cell subpopulations when stratified using more nuanced classification. Here, we profile NK cell subpopulations and elucidate the expressions of activating, NKG2D, inhibitory, NKG2A, and homing, CX3CR1, receptors on NK cell subpopulations in PD and healthy controls (HC). We analyzed cryopreserved PMBC samples using a 10-color flow cytometry panel to evaluate NK cell subpopulations in 31 individuals with sporadic PD and 27 HC participants. Here we identified significant differences in the CD56dim NK subset that changes with disease severity in PD. Furthermore, the expressions of NKG2D in all three NK cell subsets were significantly elevated in PD patients compared to HC. Notably, NKG2A expression in the CD56bright NK subset increased in PD patients with longer disease duration but there were no changes in CX3CR1. In summary, our data suggests that changes in NK cells may be influenced by the clinical severity and duration of PD.